Alkermes' Alixorexton Shows Sustained Improvement in Narcolepsy Study Interim Analysis
Alkermes plc (NASDAQ: ALKS) announced positive results from a planned interim analysis of its ongoing long-term extension study for alixorexton. The data demonstrated sustained clinically meaningful improvement in wakefulness for adults with narcolepsy type 1 and type 2.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.